Novartis unveils positive data for remibrutinib as oral treatment for CSU
In these studies, remibrutinib achieved all primary and secondary endpoints at Week 12 and the results showed that…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 23
In these studies, remibrutinib achieved all primary and secondary endpoints at Week 12 and the results showed that…
09 Nov 23
The US Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) have…
09 Nov 23
In the CorEvitas registry, a significant portion of people with treatment-resistant active PsA and using the Janssen Pharmaceuticals…
09 Nov 23
The clearance of Fruzaqla is supported by the results from two Phase 3 trials, including the FRESCO-2 trial…
09 Nov 23
The deal is expected to strengthen Alfasigma's pipeline, including the addition of a novel fixed-dose combination that has…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 23
The goal is to harness the power of large-scale life science models, accelerating the design of AAV vectors,…
09 Nov 23
The two companies will work together to identify new targets and validate them faster and with higher confidence…
08 Nov 23
Under the partnership, both firms will advance the oncology pipeline of condensate modifying therapeutics to Investigational New Drug…
08 Nov 23
The collaboration is intended to evaluate the potential of zanidatamab both as a monotherapy and in combination with…
08 Nov 23
Glenmark's current portfolio consists of 189 products authorized for distribution in the U.S. marketplace and 50 ANDA's pending…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates